每年出版 6 期
ISSN 打印: 1045-4403
ISSN 在线: 2162-6502
IF:
1.6
5-Year IF:
2.2
Immediacy Index:
0.3
Eigenfactor:
0.00058
JCI:
0.33
SJR:
0.345
SNIP:
0.46
CiteScore™::
2.5
H-Index:
67
Indexed in
Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society
Get access
摘要
Nearly 20% of all breast cancer cases are ductal carcinoma in situ (DCIS), with over 60,000 cases diagnosed each year. Many of these cases would never cause clinical symptoms or threaten the life of the woman; however, it is currently impossible to distinguish which lesions will progress to invasive disease from those that will not. DCIS is generally associated with an excellent prognosis regardless of the treatment pathway, but there is variation in treatment aggressiveness that seems to exceed the medical uncertainty associated with DCIS management. Therefore, it would seem that a significant proportion of women with DCIS receive more extensive treatment than is needed. This overtreatment of DCIS is a growing concern among the breast cancer community and has implications for both the patient (via adverse treatment-related effects, as well as out-of-pocket costs) and society (via economic costs and the public health and environmental harm resulting from health care delivery). This article discusses DCIS treatment pathways and their implications for patients and society and calls for further research to examine the factors that are leading to such wide variation in treatment decisions.
-
Lesurf Robert, Aure Miriam Ragle, Mørk Hanne Håberg, Vitelli Valeria, Lundgren Steinar, Børresen-Dale Anne-Lise, Kristensen Vessela, Wärnberg Fredrik, Hallett Michael, Sørlie Therese, Sauer Torill, Geisler Jürgen, Hofvind Solveig, Borgen Elin, Børresen-Dale Anne-Lise, Engebråten Olav, Fodstad Øystein, Garred Øystein, Geitvik Gry Aarum, Kåresen Rolf, Naume Bjørn, Mælandsmo Gunhild Mari, Russnes Hege G., Schlichting Ellen, Sørlie Therese, Lingjærde Ole Christian, Kristensen Vessela, Sahlberg Kristine Kleivi, Skjerven Helle Kristine, Fritzman Britt, Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer, Cell Reports, 16, 4, 2016. Crossref
-
KURONO Kenji, KAWASHIMA Taichi, KAWAKAMI Makio, A Case of Noninvasive Her2-positive DCIS with Multiple Recurrences Involving the Liver, Bone and Lung 3 Years after Surgery, Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 78, 6, 2017. Crossref
-
Martinez Leandro M., Robila Valentina, Clark Nicholas M., Du Wei, Idowu Michael O., Rutkowski Melanie R., Bos Paula D., Regulatory T Cells Control the Switch From in situ to Invasive Breast Cancer, Frontiers in Immunology, 10, 2019. Crossref
-
Margolis Ryan, Wessner Corinne, Stanczak Maria, Liu Ji-Bin, Li Jingzhi, Nam Kibo, Forsberg Flemming, Eisenbrey John R., Monitoring Progression of Ductal Carcinoma In Situ Using Photoacoustics and Contrast-Enhanced Ultrasound, Translational Oncology, 12, 7, 2019. Crossref
-
DURHAN Abdullah, SÜLEYMAN Marlen, KOŞMAZ Koray, ŞENLİKCİ Abdullah, ERGÜDER Ender, BAĞ Yusuf Murat, PEKCİCİ Mevlüt Recep, EREL Serap, Evaluation of Surgical and Systemic Treatment Results in Patients with Ductal Carcinoma In Situ, Journal of Contemporary Medicine, 11, 3, 2021. Crossref
-
Atwell Lauren L., Zhang Zhenzhen, Mori Motomi, Farris Paige E., Vetto John T., Naik Arpana M., Oh Karen Y., Thuillier Philippe, Ho Emily, Shannon Jackilen, Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy, Cancer Prevention Research, 8, 12, 2015. Crossref
-
Chien Ju-Chun, Liu Wen-Shan, Huang Wei-Tzu, Shih Liang-Chung, Liu Wen-Chung, Chen Yu-Chia, Chou Kang-Ju, Shiue Yow-Ling, Lin Pei-Chin, Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy, The Breast, 63, 2022. Crossref